glp-1 digital health startups Business Report for Healthtech strategy Inside CVS Ventures' $25M Bet
Description
doi: 10.3390/cancers13040866
There are no highly effective treatments for the hyperphagia and obesity
Are GLP-1s to blame
In clinical trials, participants taking the highest dose of Foundayo lost an average of 1517% of their body weight over 36 to 72 weeks, compared to roughly 2% in the placebo group
These are FDA-approved finished drug products manufactured by Novo Nordisk and Eli Lilly respectively - products that went through the FDA's full pre-market approval process for safety, effectiveness, and quality
GLP-1 agonists slow gastric emptying, which can intensify and prolong the effects of alcohol
